title stringlengths 1 1.19k | keywords stringlengths 0 668 | concept stringlengths 0 909 | paragraph stringlengths 0 61.8k | PMID stringlengths 10 11 |
|---|---|---|---|---|
Remission rates at post-measurement (three months after admission). | Anorexia Nervosa, Bulimia Nervosa | Note: AN = Anorexia Nervosa. BN = Bulimia Nervosa, Amb. = Ambulatory. | PMC10313003 | |
Discussion | anxiety, weight gain, psychiatric, comorbid disorder, AN, reduction, depressive symptoms | REMISSION, PATHOLOGY | Few empirical data examine the implementation of guideline-oriented CBT for EDs and associated outcomes in routine clinical care. In the present study, findings for full-time treatment (e.g., hospitalization) were contrasted with findings for ambulatory treatment. Across settings, patient characteristics and treatment ... | PMC10313003 |
Supporting information | PMC10313003 | |||
ED treatments in routine clinical care. | (SAV)Click here for additional data file. | PMC10313003 | ||
Purpose | To compare the efficacy and safety of the fixed-dose combination (FDC) of netarsudil 0.02%/latanoprost 0.005% ophthalmic solution (NET/LAT; Roclanda | PMC10806046 | ||
Methods | MERCURY-3 was a 6-month prospective, double–masked, randomized, multicenter, active-controlled, parallel-group, non-inferiority study. Patients (≥ 18 years) with a diagnosis of OAG or OHT in both eyes that was insufficiently controlled with topical medication (IOP ≥ 17 mmHg in ≥ 1 eye and < 28 mmHg in both eyes) were i... | PMC10806046 | ||
Results | Overall, 430 patients were randomized (NET/LAT, | PMC10806046 | ||
Conclusions | OAG | Once-daily NET/LAT was non-inferior to BIM/TIM in IOP reduction in OAG and OHT, with AEs consistent with previous findings. NET/LAT offers a compelling alternative FDC treatment option for OAG and OHT. | PMC10806046 | |
Supplementary information | The online version contains supplementary material available at 10.1007/s00417-023-06192-0. | PMC10806046 | ||
Keywords | PMC10806046 | |||
Introduction | toxicity, open-angle glaucoma, OAG, glaucoma | OCULAR HYPERTENSION, OPEN-ANGLE GLAUCOMA, PGA, GLAUCOMA, INTRAOCULAR PRESSURE | Controlling intraocular pressure (IOP), the key modifiable risk factor of conversion of ocular hypertension (OHT) to glaucoma and progression of open-angle glaucoma (OAG), remains the cornerstone of glaucoma management [IOP is determined by aqueous humour (AH) production and AH drainage through trabecular (conventional... | PMC10806046 |
Methods | PMC10806046 | |||
Study design and patients | ocular disease, inflammation, Diabetic Retinopathy, ocular infection, ocular trauma, keratitis, psychiatric, coma, occludable, glaucoma, Glaucoma, blepharitis, ocular hypotensive, angle-closure glaucoma, hypersensitivity, pseudoexfoliation | SYSTEMIC DISEASE, DIABETIC RETINOPATHY, DRY EYE, KERATITIS, BLEPHARITIS, COMA, CONJUNCTIVITIS, GLAUCOMA, ANGLE-CLOSURE GLAUCOMA, HYPERSENSITIVITY, GLAUCOMA, HERPES SIMPLEX | MERCURY-3 (NCT03284853) was a 6-month prospective, double-masked, randomized, multicenter, active-controlled, parallel-group, non-inferiority study. Participants were evaluated at one of 58 clinical sites in 11 European countries (Supplementary Table The study was conducted in accordance with the Declaration of Helsink... | PMC10806046 |
Endpoints | SECONDARY | The primary objective of this study was to establish non-inferiority (a difference of ≤ 1.5 mmHg at all nine time points through Month 3 and ≤ 1.0 mmHg at five or more of nine time points through Month 3) for NET/LAT relative to BIM/TIM, and the primary efficacy outcome was a comparison of NET/LAT relative to BIM/TIM f... | PMC10806046 | |
Procedures | hyperemia, petechiae, conjunctival blood vessels | ADVERSE EVENTS, HYPEREMIA, CORNEA, PETECHIAE, LENS, SUBCONJUNCTIVAL HEMORRHAGE, CONJUNCTIVA | Once enrolled, participants were randomly assigned 1:1 to either NET/LAT or comparator BIM/TIM, both administered as one drop, once daily (QD) in both eyes in the evening between 20:00 and 22:00 h. Treatment continued with either NET/LAT or BIM/TIM for approximately 180 days (the safety endpoint). IOP measurements were... | PMC10806046 |
Statistical methods | Two efficacy analysis sets were defined for statistical purposes, the intention-to-treat (ITT) population, which was used for all endpoints, and a per protocol (PP) set, which included participants without major protocol violations that were likely to seriously influence the primary outcome of the study as judged by a ... | PMC10806046 | ||
Results | PMC10806046 | |||
Primary efficacy endpoint | Ocular hypotensive | At the upper limit of the 95% CI difference, IOP ≤ 1.5 mmHg was achieved at all nine time points and ≤ 1.0 mmHg at the majority (six out of nine) of time points from Week 2 through Month 3 (Fig. Ocular hypotensive efficacy assessed by mean IOP at Week 2, Week 6 and Month 3. * | PMC10806046 | |
Secondary efficacy endpoints | INTRAOCULAR PRESSURE, PGA | The analysis for the primary efficacy endpoint was repeated on the PP population; the threshold for clinical non-inferiority was met at eight out of nine time points. Non-inferiority could not be confirmed overall for this population, because the upper bound 95% CI was 1.55 at the Week 6 08:00 time point. The mean IOP ... | PMC10806046 | |
Discussion | hyperemia, glaucoma, OAG, conjunctival hyperemia, TEAE, TM dysfunction | CORNEA VERTICILLATA, DISEASE PROGRESSION, HYPEREMIA, PGA, GLAUCOMA, EVENTS | This 6-month prospective, double–masked, randomized, multicenter, active-controlled, parallel-group, non-inferiority study compared, for the first time, the efficacy and safety of NET/LAT and BIM/TIM in patients with OAG and OHT. For the primary efficacy analysis, NET/LAT FDC demonstrated non-inferiority to BIM/TIM, wi... | PMC10806046 |
Acknowledgements | Valéria | POLAND, EYE, RETINA | The authors, Aerie Pharmaceuticals Ireland Ltd and Santen SA wish to acknowledge the contribution of the MERCURY-3 Study Group: Austria: Ewald Lindner (Department of Ophthalmology, Medical University Graz, Graz, Austria), Ana Prinz (Hanusch Hospital, Vienna, Austria); Czech Republic: Jitka Svačinová (University Hospita... | PMC10806046 |
Author contributions | All authors contributed to the study conception and design. Material preparation and data collection were performed by all authors. All authors recruited and saw patients involved in this study. Data analysis was performed by Santen SA and Aerie Pharmaceuticals Ireland Ltd; all authors interpreted the study data. The f... | PMC10806046 | ||
Funding | This study was funded by Aerie Pharmaceuticals Ireland Ltd. The sponsor funded, designed, and conducted the study, including data collection, management, and interpretation. Additional data management and interpretation was performed by Santen SA, with the support of Jérôme Wojcik (Data2time Sàrl, funded by Santen SA).... | PMC10806046 | ||
Declarations | PMC10806046 | |||
Ethical approval | Independent Ethics Committee (IEC) or Institutional Review Board (IRB). The clinical study protocol, protocol amendments, materials used to recruit subjects, informed consent forms (ICFs) and materials to document consent, and any other appropriate study-related documents were reviewed and approved by IECs and Competen... | PMC10806046 | ||
Ethical conduct of the study | ICH | This study was conducted in accordance with the accepted version of the Declaration of Helsinki, United States Food and Drug Administration (FDA) Law, the European Union (EU) Clinical Trials Directive 2001/20/EC, in compliance with International Council for Harmonization (ICH) good clinical practice (GCP) E6 R2 guideli... | PMC10806046 | |
Informed consent | Informed consent was obtained from all individual participants included in the study. | PMC10806046 | ||
Conflict of interest | JIB | IS reports financial support from Aerie Pharmaceuticals Ireland Ltd during the conduct of this study; and grants and personal fees from Théa and Santen, personal fees from Eye-D Pharma, Allergan-Abbvie, Horus and Alcon, and is a co-founder and shareholder of, and consultant for, MONA, outside the submitted work.KSL rep... | PMC10806046 | |
References | PMC10806046 | |||
Introduction | The American Society of Anesthesiologists published recommendations on the timing of elective surgery for patients who have recently recovered from COVID-19. | PMC10051067 | ||
Methods | infection, death | REGRESSION, INFECTION, THROMBOEMBOLIC EVENT, CARDIAC EVENTS | This cohort study was a target trial emulation with pseudorandomization to control (without recent infection) vs 2 mutually exclusive exposures (most recent infection in preoperative days 1-30 or 31-60). Eligible patients underwent major surgery from January 1 to September 30, 2021 (Alpha and Delta strain prevalence). ... | PMC10051067 |
Results | A total of 29 093 patients (mean [SD] age, 66.1 [11.4] years; 90.0% men; 67.5% White patients) underwent surgery at 123 hospitals ( | PMC10051067 | ||
Baseline Characteristics of Surgical Patients Stratified by Prior COVID-19 Infection | Abbreviations: ASA, American Society of Anesthesiologists; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); NA, not applicable; SMD, standardized mean difference.SI conversion factor: To convert albumin to grams per liter, multiply by 10.0.The “prior” in the column headings ... | PMC10051067 | ||
Weighted Logistic Regression for Outcome of Any Adverse Postoperative Outcome | thromboembolic | INFECTIOUS DISEASES, EMERGENCY | Any adverse postoperative outcome consists of 30-day mortality, cardiac outcomes, central nervous system outcomes, respiratory outcomes, infectious diseases outcomes, or thromboembolic outcomes.Emergency surgery, anesthesia, operative duration, and surgical specialty were included as postrandomization confounders; surg... | PMC10051067 |
Discussion | HAND INFECTION, COVID-19 INFECTION | These findings suggest that recent COVID-19 infection was not associated with risk of adverse postoperative outcomes, regardless of timing within the previous 60 days. A recent study found surgery within 8 weeks after a positive COVID-19 test result was associated with higher 90-day mortality vs matched controls.Study ... | PMC10051067 | |
References |
eMethods.
Click here for additional data file.
Data Sharing Statement
Click here for additional data file. | PMC10051067 | ||
Abstract | PMC10698808 | |||
Introduction | Optimizing HIV prevention may require structured approaches for providing client‐centred choices as well as community‐based entry points and delivery. We evaluated the effect of a dynamic choice model for HIV prevention, delivered by community health workers (CHWs) with clinician support, on the use of biomedical preve... | PMC10698808 | ||
Methods | We conducted a cluster randomized trial among persons (≥15 years) with current or anticipated HIV risk in 16 villages in Uganda and Kenya (SEARCH; NCT04810650). The intervention was a client‐centred HIV prevention model, including (1) structured client choice of product (pre‐exposure prophylaxis [PrEP] or post‐exposure... | PMC10698808 | ||
Results | MAY | From May to July 2021, we enrolled 429 people (212 intervention; 217 control): 57% women and 35% aged 15–24 years. Among intervention participants, 58% chose PrEP and 58% chose PEP at least once over follow‐up; self‐testing increased from 52% (baseline) to 71% (week 48); ≥98% chose out‐of‐facility service delivery. Amo... | PMC10698808 | |
Conclusions | A client‐centred dynamic choice HIV prevention intervention, including the option to switch between products and CHW‐based delivery in the community, increased biomedical prevention coverage by 27.5%. However, substantial person‐time at risk of HIV remained uncovered.Clinical Trial Number: NCT04810650 | PMC10698808 | ||
INTRODUCTION | Pre‐exposure prophylaxis (PrEP) and post‐exposure prophylaxis (PEP) are highly effective for HIV prevention [Delivery models that provide structured client‐centred choices, including the option to switch between biomedical prevention options (PrEP or PEP) over time, may help overcome these barriers. Several studies of ... | PMC10698808 | ||
METHODS | PMC10698808 | |||
Setting and participants | MAY | Between May 2021 and August 2022, we conducted a cluster randomized study in 16 villages located in rural settings with high HIV prevalence in Southwestern Uganda (Ndeija) and Western Kenya (Homa Bay and Migori). We chose a cluster randomized trial design because the intervention was delivered in the village by CHWs, p... | PMC10698808 | |
Study design and procedures | LBB, malaria | MALARIA | Prior to randomization, study villages were pair‐matched within community on village size, number of CHWs and proximity to a trading centre or highway. Randomization was conducted at a meeting of community leaders, where representatives from each matched pair selected and opened sealed envelopes to reveal the trial arm... | PMC10698808 |
Study intervention | AIDS | Building on our experience offering PrEP and PEP in rural Kenya and Uganda [CONSORT diagram.Prior to the study launch and every 6 months, both CHWs and clinicians received training on client‐centred care, including a framework for structured assessment of barriers and personalization of actions in response. Additionall... | PMC10698808 | |
Study measures | In both arms, baseline demographics, HIV risk factors, and prior PrEP and PEP use were assessed at enrolment. For endpoint ascertainment at 24 and 48 weeks of follow‐up in both arms, CHWs and research staff conducted community‐based rapid HIV testing and HIV RNA testing (Gene Xpert, Cepheid) and administered a structur... | PMC10698808 | ||
Outcomes | SECONDARY | The primary study outcome was biomedical prevention coverage, defined as the number of months during which a participant reported taking any PrEP or PEP pills divided by the number of months assessed. Biomedical prevention coverage during periods of self‐reported HIV risk was a pre‐specified secondary endpoint, compare... | PMC10698808 | |
Statistical analysis | SECONDARY | Accounting for the pair‐matched cluster randomized design [Primary and secondary outcomes were compared between arms with targeted minimum loss‐based estimation, accounting for the dependence of outcomes within clusters and adaptively adjusting for baseline covariates to maximize precision, while preserving Type‐I erro... | PMC10698808 | |
Ethical approval | The Makerere University School of Medicine Research and Ethics Committee, the Uganda National Council for Science and Technology, the Kenya Scientific and Ethics Review Unit, the National Commission for Science, Technology and Innovation, and the University of California San Francisco Committee on Human Research review... | PMC10698808 | ||
RESULTS | MAY | From May to August 2021, we enrolled 429 people (212 intervention; 217 control) in 16 villages in Southwestern Uganda and Western Kenya (Figure | PMC10698808 | |
Intervention implementation | At scheduled visits, at least 80% of 212 intervention participants were seen by CHWs and offered the DCP package. Choice varied over time (Figure Choice of intervention components over time. (a) Choice of prevention product. (b) Choice of HIV testing modality. (c) Choice of visit location.Restricted to participants off... | PMC10698808 | ||
Primary and secondary outcomes | The primary endpoint of biomedical prevention coverage, the proportion of follow‐up with self‐reported PrEP or PEP use, was ascertained in 413/429 (96%) participants: 202/212 (95%) of intervention participants and 211/217 (97%) of control participants. Average biomedical prevention coverage was 28.0% (95% CI: 23.5–32.4... | PMC10698808 | ||
DISCUSSION | fatigue, HIV self‐testing | In this cluster randomized trial, CHWs, supported by clinicians, delivered a community‐based, client‐centred dynamic choice model for prevention (DCP) to persons at risk of HIV acquisition. The DCP intervention provided clients with structured choices between biomedical prevention products (PrEP or PEP), service locati... | PMC10698808 | |
CONCLUSIONS | In this cluster randomized trial, a CHW‐led, community‐based HIV prevention intervention that provided client‐centred dynamic choices in biomedical product, HIV testing and service location increased biomedical prevention coverage, both overall and during periods of risk, compared to community‐based referral for HIV pr... | PMC10698808 | ||
COMPETING INTERESTS | DVH reports non‐financial support from ViiV Healthcare. All other authors declare no competing interests. | PMC10698808 | ||
AUTHORS’ CONTRIBUTIONS | LBB | ERK, JA, HS, EB, MN, GA, JK, CA, HNA, NS, AO, JL, EWM, GC, MRK, DVH, MLP and LBB conceptualized and designed the study. All authors participated in study operations or data collection. EWM, JP, JS and LBB performed the data analyses with input from ERK, JA, HS, EB, MN, GA, JK, CA, HNA, NS, AO, JL, GC, MCB, MRK, DVH and... | PMC10698808 | |
FUNDING | INFECTIOUS DISEASES, LUNG, ALLERGY, BLOOD, HEART | Research reported in this manuscript was supported by the U.S. National Institute of Allergy and Infectious Diseases (NIAID), the National Heart, Lung, and Blood Institute (NHLBI) and the National Institute of Mental Health (NIMH) and co‐funded under award number U01AI150510. | PMC10698808 | |
DISCLAIMER | The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. | PMC10698808 | ||
Supporting information |
Click here for additional data file. | PMC10698808 | ||
ACKNOWLEDGEMENTS | The SEARCH study gratefully acknowledges the Kenya Ministry of Health, Uganda Ministry of Health, our research teams and administrative teams in San Francisco, Kenya and Uganda, collaborators and advisory boards, and especially all communities and participants involved. We also thank Catherine Koss, Monica Ghandi, Hana... | PMC10698808 | ||
DATA AVAILABILITY STATEMENT | A complete de‐identified patient dataset sufficient to reproduce the study findings will be made available approximately 1 year after completion of the ongoing trial (NCT04810650), following approval of a concept sheet summarizing the analyses to be performed. Further inquiries can be directed to the SEARCH Scientific ... | PMC10698808 | ||
REFERENCES | PMC10698808 | |||
Background | Dyspnea, CAD, angina | CORONARY ARTERY DISEASE, CAD | Dyspnea is a frequent symptom in patients with stable coronary artery disease (CAD) and is recognized as a possible angina equivalent. | PMC10449717 |
Objectives | CAD, dyspnea, angina pectoris | CAD | This study was to assess the impact of percutaneous coronary intervention (PCI) on dyspnea, quality of life, and angina pectoris in patients with stable CAD. | PMC10449717 |
Methods | CAD, Seattle Angina, dyspnea, angina pectoris | REGRESSION, CAD | The prospective, multi-center PLA-pCi-EBO-pilot trial included 144 patients with symptomatic stable CAD and successful PCI. The prespecified endpoints angina pectoris (Seattle Angina Questionnaire–SAQ) and dyspnea (NYHA scale) were assessed 6 months after PCI. Predictors for symptomatic improvement were assessed with u... | PMC10449717 |
Results | dyspnea | Patients with concomitant dyspnea had worse SAQ physical limitation scores at baseline (49.5 ± 21.0 vs 58.9 ± 22.0, | PMC10449717 | |
Conclusion | CAD, dyspnea | CAD | PCI effectively reduced dyspnea, which is a frequent and demanding symptom in patients with CAD. The German Clinical Trials Register registration number is DRKS0001752 ( | PMC10449717 |
Graphical abstract | PMC10449717 | |||
Supplementary Information | The online version contains supplementary material available at 10.1007/s00392-022-02107-x. | PMC10449717 | ||
Keywords | Open Access funding enabled and organized by Projekt DEAL. | PMC10449717 | ||
Introduction | Dyspnea, CAD, dyspnea, angina pectoris | DISEASE, CORONARY ARTERY DISEASE, CAD, LEFT MAIN CORONARY ARTERY DISEASE | Coronary artery disease (CAD) is an often debilitating disease and the symptomatic burden, including angina pectoris and dyspnea, can be accompanied by starkly impaired quality of life [The EXCEL trial found that dyspnea was present in 73% of patients with left main coronary artery disease [Dyspnea often is multi-facto... | PMC10449717 |
Methods | PMC10449717 | |||
Study population | CCS angina, dyspnea, impaired vision, chest pain, anemia, CAD, valvular disease, angina pectoris | PULMONARY DISEASE, ANEMIA, CONCOMITANT DISEASE, CAD | This study was designed as a prospective randomized and controlled trial to investigate the effect of visual demonstration of successful PCI on quality of life and angina pectoris in patients with symptomatic stable CAD. The details of the study design have been published previously [Between April 2019 and September 20... | PMC10449717 |
Symptomatic evaluation of angina pectoris and dyspnea | Dyspnea, angina pectoris | Patient-reported angina pectoris symptom burden was evaluated using the SAQ [Dyspnea was determined according to the NYHA classification pre PCI, and 6 months after PCI [Patients with missing data in one of the endpoints were excluded from the respective analysis. As there was no difference between the intervention and... | PMC10449717 | |
Statistical analysis | CAD, dyspnea | REGRESSION, CAD | For the present analyses, patients of the randomized controlled trial were first divided into those with “concomitant dyspnea” and those without “concomitant dyspnea.” Categorical data are presented as absolute (As it can be difficult to clearly distinguish dyspnea of cardiac origin from dyspnea due to other comorbidit... | PMC10449717 |
Results | PMC10449717 | |||
Differences in angina symptoms and quality of life in patients with and without concomitant dyspnea | ±, Angina pectoris, dyspnea | Angina pectoris symptom burden was evaluated using the SAQ subscales. At baseline, patients with concomitant dyspnea had a worse physical limitation score (49.5 ± 21.0 vs 58.9 ± 22.0, Differences in angina symptoms and quality of life in patients presenting with and without dyspnea. PCI led to a marked relief in sympto... | PMC10449717 | |
Discussion | PMC10449717 | |||
Worse symptomatic outcome after PCI in patients presenting with dyspnea | dyspnea, angina, Dyspnea, CAD, angina pectoris, COPD, obstructive pulmonary disease | COPD, PULMONARY DISEASE, OBSTRUCTIVE PULMONARY DISEASE, CAD | Dyspnea and angina pectoris correlate in patients with stable CAD. It is, however, not clear what the presence of dyspnea in addition to angina pectoris means for the symptomatic response after PCI. Patients who presented with concomitant dyspnea had a slightly higher body mass index (29 vs 27 kg/mChronic obstructive p... | PMC10449717 |
PCI effectively reduces dyspnea | Myocardial ischemia, CAD, dyspnea | MYOCARDIAL ISCHEMIA, CAD | Myocardial ischemia often manifests as dyspnea [Despite being a frequent and relevant symptom of CAD [The exclusion criteria that we employed limit the generalizability of our results to a specific patient population, i.e., patients with symptomatic CAD and without significant comorbidities. However, this group is nume... | PMC10449717 |
Predictors for improvement of dyspnea | dyspnea, angina, microvascular dysfunction, atypical angina, diabetes | DIABETIC POLYNEUROPATHY, DISEASE, ATYPICAL ANGINA PECTORIS, PULMONARY DISEASE, DIABETES | We found that the presence of atypical angina pectoris symptoms increases, and that diabetes reduces the probability of less dyspnea 6 months after PCI. Data about predictors for changes of dyspnea after PCI are sparse. Qintar et al. investigated the effect of PCI in patients with chronic total occlusion on dyspnea [Th... | PMC10449717 |
Limitations | cardiac dyspnea, dyspnea | SECONDARY | This current analysis is a secondary analysis of a randomized controlled trial, which was not powered for the present analysis strategy; generalization is therefore limited. As there was no sham control for PCI, it is not possible to attribute all improvements in symptomatic outcome after PCI exclusively to the PCI. Th... | PMC10449717 |
Conclusions | dyspnea, angina, Dyspnea, CAD, angina pectoris | CAD | Dyspnea is often underappreciated in the context of stable CAD and data on the occurrence of dyspnea following PCI is scarce or totally lacking. We examined a very well-characterized patient cohort and found that dyspnea is a frequent and relevant symptom in patients with stable CAD. The majority of patients in our stu... | PMC10449717 |
Supplementary Information | Below is the link to the electronic supplementary material.Supplementary file1 (DOCX 72 kb) | PMC10449717 | ||
Abbreviations | Angina, angina | Coronary artery diseaseCanadian cardiovascular society angina grading scaleChronic obstructive pulmonary diseasePercutaneous coronary interventionSeattle Angina Questionnaire | PMC10449717 | |
Funding | Open Access funding enabled and organized by Projekt DEAL. This work was supported by the Doktor Robert Pfleger-Stiftung Bamberg, Germany. | PMC10449717 | ||
Data availability | The data underlying this article will be shared on reasonable request to the corresponding author. | PMC10449717 | ||
Declarations | PMC10449717 | |||
Conflict of interest | The authors have no conflict of interests to declare. | PMC10449717 | ||
References | PMC10449717 | |||
Introduction | colon cancer | COLON CANCER | Three nomograms for predicting the outcomes of early- and late-onset colon cancer (COCA) among patients not stratified by age were constructed using data in the Epidemiology and End Results (SEER) database (1975–2019). The accuracy of the nomogram was then assessed. | PMC10620318 |
Method | Clinical data of 6107 patients with COCA were obtained from the SEER database. The patients were randomly divided into training and validation cohorts in a ratio of 7:3. Univariate and multivariate COX analyses of factors that could independently impact the prognosis of COCA were performed, and the corresponding nomogr... | PMC10620318 | ||
Result | colon cancer, Tumor | BRAIN METASTASIS, COLON CANCER, TUMOR | Tumor primary site, ethnicity, and serum carcinoembryonic antigen (CEA) level significantly impacted the prognosis of colon cancer. Race, brain metastasis, and CEA were independent factors for predicting COCA prognosis. C-index, ROC, and calibration curves demonstrated that the three nomograms were accurate and superio... | PMC10620318 |
Conclusion | late-onset colon cancer | COLON CANCER | Three nomograms for patients not stratified by age, early-onset colon cancer, and late-onset colon cancer were constructed. The accuracies of the nomograms were good and were all superior to the conventional TNM staging system. The early- and late-onset COCA nomograms are useful for clinical management and individualiz... | PMC10620318 |
Keywords | PMC10620318 | |||
Introduction | obesity, tumor-node-metastasis, AJCC, CRC, cancer, malignant tumors, Early-onset, early-onset, Colorectal cancer, UICC, Cancer | OBESITY, CANCER, MALIGNANT TUMORS, COLORECTAL CANCER, PATHOGENESIS, CANCER | Colorectal cancer (CRC) is the fourth most fatal cancer globally, killing nearly 9 million people annually. In addition to an aging population and dietary habits, several factors, such as obesity, lack of physical activity, and smoking, increase the risk of CRC (Dekker et al. Early-onset COCA refers to COCA diagnosed a... | PMC10620318 |
Materials and methods | PMC10620318 | |||
Patients selection | This was a retrospective cohort study in which data were obtained from the surveillance, epidemiology, and final results database (Flow chart for selecting COCA patients included in the present study | PMC10620318 | ||
Clinical variables and outcomes | tumor, death | BRAIN METASTASIS, TUMOR, LUNG METASTASIS, BONE METASTASIS, LIVER METASTASIS | The clinical variables analyzed in this study include age, race, gender, tumor primary site, tumor size, TNM stage based on the 8th edition of AJCC guidelines, serum CEA level, nerve invasion, lymph node metastasis, liver metastasis, lung metastasis, bone metastasis, and brain metastasis. The primary outcome analyzed w... | PMC10620318 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.